Pyrazinoylguanidine downregulates the glucose fatty-acid, cycle in hypertensive, hyperinsulinemic diabetic patients

E. S. Vesell, C. E. Chambers, T. DeAngelo Seaton, G. T. Passananti, L. M. Demers, K. H. Beyer

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Eight hypertensive patients with noninsulin dependent diabetes mellitus (NIDDM) were administered the experimental drug pyrazinoylguanidine (PZG) either alone or in combination with calcium-channel or β-blockers. This treatment appeared to 'downregulate' the glucose fatty acid cycle and reduced both systolic and diastolic blood pressures and mean body weight. Patients served as their own controls in this dose-escalation study, which included placebo treatment (baseline) 3 weeks, 300 mg PZG for 3 weeks and 600 mg for 3 weeks. PZG reduced increased serum concentrations of free fatty acids (FFA), glucose, and triglycerides (TC). TC concentrations correlated inversely with serum HDL-cholesterol concentrations. The beta-blockers used by several patients increased their FFA, glucose, insulin and TC concentrations, as well as blunting their response to PZG. The calcium-channel blockers exerted these effects to a much lesser extent. PZG reduced or abolished glycosuria, related to PZG's capacity to decrease hyperglycemia. Withdrawal of PZG restored glycosuria, as blood sugar increased. PZG was well tolerated. No patient reported any adverse effect or missed a weekly clinic visit (12 weeks). PZG deserves further study as supplementary and/or replacement therapy in NIDDM patients who are hypertensive and hyperlipidemic.

Original languageEnglish (US)
Pages (from-to)1234-1245
Number of pages12
JournalJournal of Clinical Pharmacology
Volume34
Issue number12
Publication statusPublished - Dec 1 1994

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Vesell, E. S., Chambers, C. E., DeAngelo Seaton, T., Passananti, G. T., Demers, L. M., & Beyer, K. H. (1994). Pyrazinoylguanidine downregulates the glucose fatty-acid, cycle in hypertensive, hyperinsulinemic diabetic patients. Journal of Clinical Pharmacology, 34(12), 1234-1245.